Group 1: Commercial Aerospace - The Chinese commercial aerospace sector is entering a new phase aimed at large-scale launches and commercial closed-loop systems, with significant breakthroughs expected in rocket capacity over the next 3 to 5 years [1] - By 2025, China's commercial aerospace is projected to complete 50 launches, accounting for 54% of total space launches, with 25 commercial rockets launched and 311 commercial satellites in orbit, representing 84% of total satellites [1] - The capital market for commercial aerospace companies is accelerating, with several leading firms preparing for IPOs, including Blue Arrow Aerospace and Zhongke Aerospace [1] Group 2: Public Fund Performance - The latest public fund reports reveal that the top ten holdings include companies like Zhongji Xuchuang, Ningde Times, and Tencent, with notable increases in holdings for companies like Zhongji Xuchuang, which saw an increase of 22.602 billion yuan [2] - The automotive industry is facing cost pressures due to rising prices of memory chips and metals, impacting supply chain dynamics and competition [2] Group 3: Biopharmaceutical Industry - Over 50 biopharmaceutical companies have disclosed their 2025 performance forecasts, with nearly 50% showing positive expectations, particularly in the CXO sector, where WuXi AppTec anticipates a revenue increase of approximately 15.84% [3] - The biopharmaceutical industry is expected to enter a new phase of high-quality development as structural reforms and supportive policies continue to evolve [3] Group 4: Fundraising and Market Trends - The public fund market has seen a resurgence, with several equity funds raising over 7 billion yuan, indicating a positive trend in active equity fund performance [4] - The Shanghai Suiruan Technology Co., Ltd. has received approval for its IPO, aiming to raise 6 billion yuan for product development and business expansion [5] Group 5: Aluminum Market - The aluminum market has shown strong performance, with prices rising over 12% since mid-December 2025, supported by favorable macroeconomic conditions and demand for aluminum in various applications [6] - The copper-aluminum price ratio exceeding 4 suggests a potential shift towards aluminum in sectors like air conditioning, indicating new demand growth [6] Group 6: Banking Sector - Five listed banks have reported a year-on-year increase in net profit for 2025, with improvements in non-performing loan ratios for three banks [9] - The banking sector is expected to maintain stable performance, supported by improved funding costs and a potential stabilization of net interest margins [9] Group 7: Chemical Industry - The chemical industry is experiencing positive performance, with over 60% of companies reporting improved earnings, driven by rising prices of certain chemical products [10] - The DOP market is expected to maintain upward momentum due to strong raw material prices and limited supply, indicating a stable support for pricing [10]

Core Viewpoint - The biopharmaceutical industry is showing positive performance, with over 50 companies disclosing earnings forecasts for 2025, and nearly half of them expecting growth. The CXO sector, particularly leading companies like WuXi AppTec, is expected to see significant revenue and profit increases, indicating a favorable trend for the industry as it moves towards high-quality development in the coming years [1][6]. Group 1: Company Performance - Among the over 50 biopharmaceutical companies that disclosed earnings forecasts, 27 are expected to report positive results, with 18 anticipating profit increases, 5 slight increases, and 4 turning losses into profits [1]. - WuXi AppTec is projected to achieve approximately 45.456 billion yuan in revenue for 2025, a year-on-year increase of about 15.84%, and a net profit of approximately 19.151 billion yuan, reflecting a growth of about 102.65% [1][3]. - Shanghai Yizhong expects a net profit of 60 to 70 million yuan in 2025, representing a year-on-year increase of 760.18% to 903.54%, driven by the inclusion of its core product in the national medical insurance directory [2]. - Yiling Pharmaceutical anticipates a net profit of 1.2 to 1.3 billion yuan in 2025, recovering from losses, as it focuses on long-term development and market expansion [2]. - Teva Pharmaceutical is expected to achieve a net profit of 70 to 90 million yuan in 2025, with a growth rate of 241.55% to 339.13%, attributed to marketing transformation and product recovery [3]. Group 2: Industry Trends - The CXO sector is experiencing a positive trend, with many companies reporting sustained order growth that is translating into improved performance [3][6]. - The overall demand for CRO and CDMO services is recovering, driven by the resumption of investment and financing, as well as the implementation of significant policies in the industry [6][7]. - The pharmaceutical sector is undergoing a valuation recovery, with the PE ratio steadily increasing since the first quarter of 2025, indicating a positive outlook for the industry [6][7]. - The number and scale of license-out transactions in 2025 have reached record highs, showcasing the global competitiveness of domestic new drugs [7]. - The industry is entering a critical phase of innovation realization and global layout, with investment opportunities focusing on companies with genuine global competitiveness [8].

Group 1 - The A-share market experienced fluctuations at relatively high levels in Q4 2025, with a slight decrease in overall equity positions of public funds compared to Q3 2025 [1][2] - The average equity positions for stock and mixed funds were 89.06% and 81.05%, respectively, showing a minor decline from the previous quarter [2] - Major holdings in public funds included leading light module companies, with Zhongji Xuchuang and Xinyi Sheng surpassing Ningde Times and Tencent Holdings to become the top two heavyweights [1][4] Group 2 - Several actively managed equity funds significantly increased their positions, with notable examples including Bosera Huixing and GF Chengxiang, which raised their equity positions by 12.31 and 10.3 percentage points, respectively [2] - Fund managers expressed optimism about the A-share market for 2026, citing potential dual benefits from domestic and international liquidity [3][9] - The focus on technology sectors continued, with managers identifying investment opportunities in storage chips, solid-state batteries, and humanoid robots [7][10] Group 3 - The top 50 heavyweights in public funds were primarily concentrated in information technology, consumer goods, and investment sectors, with 18 stocks in the information technology sector [4][6] - AI-related stocks gained prominence, with Zhongji Xuchuang, Xinyi Sheng, and Hanwujing entering the top seven heavyweights due to the AI boom [4][6] - The number of innovative drug companies in the top 50 heavyweights decreased from eight to five by the end of Q4 2025, indicating a shift in investment focus [5] Group 4 - Fund managers anticipate that the AI investment theme will continue to be a primary focus, with expectations for rapid growth in AI applications in the coming years [9][10] - The investment strategy is shifting towards AI applications, including smart driving, edge AI, and humanoid robots, as the industry matures [9][10] - The overall sentiment among fund managers is that the AI-driven technology market will remain a significant area of investment for the next several years [9][10]

Group 1 - A-share market is experiencing a concentrated release of performance forecasts, with 640 companies disclosing their 2025 performance predictions, of which 248 companies are expected to have positive results, accounting for 38.75% [1] - Among the companies, 130 are expected to have a net profit growth exceeding 100%, with 29 companies exceeding 300% and 11 companies exceeding 500% [1] - The top three companies in terms of profit growth are Huisheng Biological, Southern Precision, and Shanghai Yizhong, with expected net profit growth rates of 1444.54%, 1417.00%, and 903.54% respectively [1] Group 2 - The hard technology sector is highlighted as a major growth area, driven by the increasing demand for AI infrastructure and computing power, leading to significant profit increases for companies in storage and PCB sectors [2] - In the storage sector, Baiwei Storage expects a net profit of 850 million to 1 billion yuan in 2025, representing a year-on-year growth of 427.19% to 520.22%, with a quarterly net profit growth of up to 1449.67% [2] - Demingli, another storage company, anticipates revenues of 10.3 billion to 11.3 billion yuan in 2025, with a net profit growth of up to 128.21% [2] Group 3 - PCB leader Shenghong Technology forecasts a net profit of 4.16 billion to 4.56 billion yuan in 2025, with a year-on-year growth of 260.35% to 295%, driven by high-end product mass production in the AI computing field [3] - Other technology companies like Changxin Bochuang and Zhongke Lanyun also predict significant profit growth, with some companies expecting to double their earnings [3] - The growth in the hard technology sector is seen as a direct reflection of the industrialization of AI technology, with increased demand for high-end storage and PCB hardware [3]

Investment Rating - The report maintains a positive outlook on the CXO sector for the year 2026, indicating strong demand and recovery in global orders [3][26]. Core Insights - Illumina's release of the Billion Cell Atlas marks a significant advancement in life sciences, transitioning from static genomic data to a comprehensive dataset that integrates AI for drug discovery [3][8]. - Regulatory developments in China and the US are accelerating drug approval processes, with China's implementation of eCTD and the US FDA's support for Bayesian methods enhancing clinical trial efficiency [3][23]. - The CXO sector is expected to see robust growth, supported by major players like Lonza and WuXi AppTec, who are expanding capacity and reporting increased order volumes [3][26]. Summary by Sections Industry Frontiers - Illumina's Billion Cell Atlas is the largest human genome perturbation dataset to date, aimed at accelerating drug discovery through AI [3][8]. - Regulatory dynamics indicate a race for faster drug approvals, with China's NMPA adopting eCTD and the FDA endorsing Bayesian statistical methods for clinical trials [3][23]. - The global order recovery is evident, with a positive outlook for the CXO sector throughout 2026, as major companies report growth and increased demand [3][26]. Capital Trends - GSK's acquisition of RAPT Therapeutics for $2.2 billion focuses on developing an anti-IgE monoclonal antibody for food allergies, highlighting the potential in the allergy treatment market [4][31]. - Novartis has entered a $1.5 billion agreement with SciNeuro to advance a new antibody project targeting Alzheimer's disease, indicating ongoing investment in neurodegenerative treatments [4][36]. Weekly Perspective - The report emphasizes the transition to an AI-driven era in drug discovery, suggesting that previous advantages in research may diminish as the landscape evolves [5][37]. - The demand for CXO services is expected to remain strong, driven by AI-enabled drug discovery and regulatory advancements [5][38].

Market Overview - The medical services sector increased by 0.18% on January 21, with Nanmo Biology leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Gainers in Medical Services - Nanmo Biology (688265) closed at 49.79, up 7.01% with a trading volume of 20,000 shares and a transaction value of 98.02 million [1] - Hite Biology (300683) closed at 29.67, up 5.74% with a trading volume of 107,800 shares and a transaction value of 32.2 million [1] - Dean Diagnostics (300244) closed at 26.46, up 5.59% with a trading volume of 796,300 shares and a transaction value of 2.13 billion [1] - ST Zhongzhu (600568) closed at 2.64, up 5.18% with a trading volume of 376,500 shares and a transaction value of 9.81 million [1] - Tongce Medical (600763) closed at 46.51, up 4.99% with a trading volume of 198,600 shares and a transaction value of 911 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 18.72, down 4.44% with a trading volume of 74,500 shares and a transaction value of 143 million [2] - Hongbo Pharmaceutical (301230) closed at 46.36, down 1.88% with a trading volume of 131,200 shares and a transaction value of 614 million [2] - Chengda Pharmaceutical (301201) closed at 41.39, down 1.76% with a trading volume of 36,600 shares and a transaction value of 153 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 50.51 million from institutional investors, while retail investors experienced a net outflow of 375 million [2] - The sector's overall capital flow indicates a strong interest from institutional and speculative investors, with retail investors pulling back [2][3] Notable Capital Inflows - Sanbo Brain Science (301293) had a net inflow of 91.48 million, representing 9.03% of its total capital [3] - Tongce Medical (600763) saw a net inflow of 83.46 million, accounting for 9.16% of its total capital [3] - BGI Genomics (300676) recorded a net inflow of 51.81 million, which is 8.37% of its total capital [3]

Core Viewpoint - The Shanghai 180 ETF Index Fund closely tracks the Shanghai 180 Index, which reflects the overall performance of 180 large-cap and liquid stocks in the Shanghai securities market [2] Group 1: Index Performance - As of January 20, 2026, the Shanghai 180 Index rose by 0.08%, with notable increases in constituent stocks such as China Chemical (+10.01%), China Power Construction (+7.02%), and Hengli Petrochemical (+6.62%) [1] - The Shanghai 180 ETF Index Fund achieved a four-day consecutive increase, with the latest price reported at 1.26 yuan [1] - The fund's average daily trading volume over the past year was 256.26 million yuan, with a turnover rate of 0.11% on January 20, 2026 [1] Group 2: Fund Metrics - The fund's Sharpe ratio since inception is 2.13, indicating a favorable risk-adjusted return [1] - The maximum drawdown for the fund year-to-date is 1.30%, with a relative benchmark drawdown of 0.06% [1] - The management fee for the fund is 0.15%, and the custody fee is 0.05% [1] Group 3: Top Holdings - As of December 31, 2025, the top ten weighted stocks in the Shanghai 180 Index account for 25.29% of the index, including Kweichow Moutai, Zijin Mining, and China Ping An [2] - The top ten stocks by weight are Kweichow Moutai (4.21%), Zijin Mining (3.78%), and China Ping An (2.31%), among others [3]

Core Insights - The CRO industry in China is experiencing significant growth, with the market size expected to expand from 90 billion yuan in 2021 to 126 billion yuan by 2024, reflecting a compound annual growth rate (CAGR) of 28%, which is substantially higher than the global average of 10% [13][26] - The industry is characterized by a clear competitive landscape, with WuXi AppTec as the dominant player, achieving revenue exceeding 20 billion yuan, while other key players include Kanglong Chemical, Tigermed, and Kelun Pharmaceutical [17][20] Industry Overview - Contract Research Organizations (CROs) are specialized entities that undertake drug development responsibilities on behalf of pharmaceutical companies, helping to reduce costs and risks while ensuring compliance [1] - The CRO industry is divided into preclinical and clinical segments, with preclinical CROs focusing on drug discovery and safety evaluations, while clinical CROs handle clinical trials and data management [1] Industry Development History - The CRO industry in China began in 1996 with the establishment of the first joint venture, and has evolved from a lack of formal organizations to a competitive landscape dominated by local leaders [9] - The industry has undergone significant changes, including the implementation of Good Clinical Practice (GCP) in 2003 and the introduction of the Marketing Authorization Holder (MAH) system, which has facilitated the growth of CRO services [11] Market Demand and Growth - The number of New Drug Applications (NDA) in China has been increasing, from 210 in 2021 to an expected 320 by 2024, driving demand for CRO services [14] - The global CRO market is projected to grow from 71 billion USD in 2021 to 90 billion USD by 2024, driven by increased healthcare demands due to aging populations and the COVID-19 pandemic [13] Competitive Landscape - The competitive structure of the Chinese CRO industry is categorized into three tiers, with WuXi AppTec leading the first tier, followed by Kanglong Chemical and Tigermed in the second tier, and smaller firms in the third tier [17] - Most companies are diversifying their services to include both CRO and CDMO (Contract Development and Manufacturing Organization) capabilities, enhancing operational efficiency [20] Regional Market Dynamics - The Yangtze River Delta region dominates the CRO market in China, accounting for approximately 43% of the market share, followed by the Beijing-Tianjin-Hebei region at 23% and the Pearl River Delta at 19% [23] Future Outlook - The Chinese CRO market is expected to continue its growth trajectory, potentially exceeding 144 billion yuan by 2028, supported by favorable policies and increasing demand for innovative therapies [26] - Despite challenges such as rising compliance costs and market saturation, the overall outlook remains positive, with expectations of sustained double-digit growth over the next five years [26]

Core Viewpoint - The company has released its 2025 performance forecast, projecting revenue of 45.46 billion yuan (+15.8%) and a net profit attributable to shareholders of 19.15 billion yuan (+102.7%), indicating better-than-expected performance [1] Revenue and Profit Forecast - For 2025, the company expects revenue of 45.46 billion yuan, with a 15.8% year-on-year growth, and a net profit of 19.15 billion yuan, reflecting a 102.7% increase [2] - The projected revenue for 2026 and 2027 is 51.55 billion yuan (+13.4%) and 58.82 billion yuan (+14.1%), respectively [2] Business Growth and Performance - The growth rate of the continuing operations revenue is forecasted at 21.4%, exceeding previous guidance of 17-18% [1] - The company anticipates that the Chemistry business will maintain rapid growth, driven by TIDES and other business segments [1] Quarterly Performance Insights - In Q4 2025, the company expects revenue of 12.6 billion yuan (+9.2%) and a net profit of 7.08 billion yuan (+142.5%) [1] - The Non-IFRS net profit margin for Q4 2025 is projected to be 35.1%, showing stability compared to Q3 2025 and significant improvement from Q4 2024 [1] Future Profitability Potential - The company expects to generate approximately 4.16 billion yuan from the sale of equity interests and 1.43 billion yuan from the sale of clinical CRO and SMO businesses in 2025 [1] - The profitability potential for 2026 remains promising due to anticipated large orders and a stable recovery in overseas demand [1]

Market Overview - The precision medicine sector experienced a decline of 1.69% on January 20, with WuXi AppTec leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Notable gainers included: - ST Xiangxue, closing at 9.72 with a rise of 7.05% and a trading volume of 193,900 shares [1] - Zhaoli Pharmaceutical, closing at 17.50 with a rise of 3.18% and a trading volume of 270,200 shares [1] - Major decliners included: - WuXi AppTec, closing at 99.46 with a decline of 2.86% and a trading volume of 481,100 shares [2] - Guomai Technology, closing at 11.56 with a decline of 2.45% and a trading volume of 361,100 shares [2] Capital Flow - The precision medicine sector saw a net outflow of 346 million yuan from institutional investors, while retail investors had a net inflow of 400 million yuan [2][3] - Specific stock capital flows indicated: - DIAN Diagnostics had a net inflow of 62.76 million yuan from institutional investors [3] - ST Xiangxue experienced a net outflow of 22.01 million yuan from retail investors [3]